ASCO Annual Meeting: Renal Cell Carcinoma | Conference

Chung-Han Lee, MD, PhD, on TKI/IO Combination Therapy for Non–Clear Cell RCC
June 25, 2021

At ASCO 2021, Chung-Han Lee, MD, PhD, discussed an ongoing trial looking at pembrolizumab plus lenvatinib as frontline therapy for non–clear cell renal cell carcinoma.

Robert J. Motzer, MD, on Main HRQOL Takeaways From Phase 3 CLEAR Trial
June 17, 2021

Motzer discussed time to deterioration end points for patients with advanced renal cell carcinoma treated with pembrolizumab and lenvatinib in the first-line setting.

Recommended Dose of Pembrolizumab Plus Cabozantinib Combo Induced Response in mRCC
June 09, 2021

The recommended phase 2 dose of pembrolizumab plus cabozantinib induced a response with a manageable safety profile for patients with mRCC.